Anika Therapeutics (ANIK) Competitors $16.97 -0.46 (-2.64%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ANIK vs. ANGO, CERS, OSUR, UTMD, ARAY, VAPO, SIBN, SRDX, WST, and COOShould you be buying Anika Therapeutics stock or one of its competitors? The main competitors of Anika Therapeutics include AngioDynamics (ANGO), Cerus (CERS), OraSure Technologies (OSUR), Utah Medical Products (UTMD), Accuray (ARAY), Vapotherm (VAPO), SI-BONE (SIBN), Surmodics (SRDX), West Pharmaceutical Services (WST), and Cooper Companies (COO). These companies are all part of the "medical" sector. Anika Therapeutics vs. AngioDynamics Cerus OraSure Technologies Utah Medical Products Accuray Vapotherm SI-BONE Surmodics West Pharmaceutical Services Cooper Companies Anika Therapeutics (NASDAQ:ANIK) and AngioDynamics (NASDAQ:ANGO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership, community ranking and risk. Is ANIK or ANGO more profitable? Anika Therapeutics has a net margin of -59.40% compared to AngioDynamics' net margin of -83.95%. Anika Therapeutics' return on equity of -2.22% beat AngioDynamics' return on equity.Company Net Margins Return on Equity Return on Assets Anika Therapeutics-59.40% -2.22% -1.75% AngioDynamics -83.95%-5.86%-4.17% Do analysts prefer ANIK or ANGO? Anika Therapeutics presently has a consensus price target of $24.50, indicating a potential upside of 44.37%. AngioDynamics has a consensus price target of $12.00, indicating a potential upside of 75.70%. Given AngioDynamics' stronger consensus rating and higher possible upside, analysts plainly believe AngioDynamics is more favorable than Anika Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anika Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50AngioDynamics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor ANIK or ANGO? AngioDynamics received 64 more outperform votes than Anika Therapeutics when rated by MarketBeat users. However, 64.33% of users gave Anika Therapeutics an outperform vote while only 61.06% of users gave AngioDynamics an outperform vote. CompanyUnderperformOutperformAnika TherapeuticsOutperform Votes30364.33% Underperform Votes16835.67% AngioDynamicsOutperform Votes36761.06% Underperform Votes23438.94% Which has more volatility and risk, ANIK or ANGO? Anika Therapeutics has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, AngioDynamics has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Which has preferable valuation and earnings, ANIK or ANGO? Anika Therapeutics has higher earnings, but lower revenue than AngioDynamics. Anika Therapeutics is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnika Therapeutics$166.66M1.49-$82.67M-$6.65-2.55AngioDynamics$303.91M0.91-$184.35M-$6.09-1.12 Does the media prefer ANIK or ANGO? In the previous week, AngioDynamics had 1 more articles in the media than Anika Therapeutics. MarketBeat recorded 2 mentions for AngioDynamics and 1 mentions for Anika Therapeutics. AngioDynamics' average media sentiment score of 1.22 beat Anika Therapeutics' score of 0.00 indicating that AngioDynamics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anika Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AngioDynamics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in ANIK or ANGO? 91.5% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 89.4% of AngioDynamics shares are owned by institutional investors. 7.9% of Anika Therapeutics shares are owned by insiders. Comparatively, 5.4% of AngioDynamics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryAnika Therapeutics and AngioDynamics tied by winning 9 of the 18 factors compared between the two stocks. Ad Behind the Markets⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> Get Anika Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANIK vs. The Competition Export to ExcelMetricAnika TherapeuticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$248.61M$4.51B$5.38B$8.84BDividend YieldN/A36.80%5.13%4.09%P/E Ratio-2.5526.03105.1417.83Price / Sales1.4946.931,233.15158.41Price / Cash3.4653.5740.4136.29Price / Book1.385.947.096.50Net Income-$82.67M$13.99M$119.65M$226.22M7 Day Performance-1.62%3.27%2.25%4.03%1 Month Performance-30.85%4.64%-2.33%4.92%1 Year Performance-17.54%47.15%33.98%29.30% Anika Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANIKAnika Therapeutics3.6104 of 5 stars$16.97-2.6%$24.50+44.4%-17.5%$248.61M$166.66M-2.55357ANGOAngioDynamics4.743 of 5 stars$6.95+3.1%$12.00+72.7%-0.3%$282.38M$303.91M-1.11748Positive NewsCERSCerus2.8305 of 5 stars$1.69+1.8%$3.63+115.1%+8.5%$312.92M$156.37M-15.32625Positive NewsOSUROraSure Technologies4.5154 of 5 stars$3.85+1.0%$6.67+73.2%-46.5%$287.17M$405.47M25.40638UTMDUtah Medical Products3.47 of 5 stars$64.57+0.6%N/A-20.8%$218.89M$50.22M15.03180Positive NewsARAYAccuray4.7058 of 5 stars$1.89+2.7%$9.00+377.5%-29.8%$189.57M$446.55M-10.94987Analyst RevisionNews CoverageVAPOVapothermN/A$2.17-0.5%N/A-17.2%$13.59M$68.67M0.00290High Trading VolumeSIBNSI-BONE4.2817 of 5 stars$12.31+1.3%$23.00+86.9%-29.9%$516.24M$138.89M-13.38350Analyst ForecastInsider TradeSRDXSurmodics4.2084 of 5 stars$39.19+0.1%$50.00+27.6%+15.1%$559.24M$126.08M-48.38376Analyst ForecastWSTWest Pharmaceutical Services4.9699 of 5 stars$320.28+2.8%$460.33+43.7%-9.8%$23.19B$2.95B47.5210,600COOCooper Companies3.6612 of 5 stars$99.96+0.9%$117.00+17.1%+18.9%$19.91B$3.59B55.6915,000Analyst Downgrade Related Companies and Tools Related Companies AngioDynamics Alternatives Cerus Alternatives OraSure Technologies Alternatives Utah Medical Products Alternatives Accuray Alternatives Vapotherm Alternatives SI-BONE Alternatives Surmodics Alternatives West Pharmaceutical Services Alternatives Cooper Companies Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ANIK) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anika Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anika Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
